Page results
-
The service is staffed by fully qualified doctors and health care professionals who also have additional training in complementary medicine. They work within a multidisciplinary team…
-
If ataxia runs in your family, you can get tested to see if you have the genetic mistake for it Ataxia is a health condition that causes problems with movement…
-
There are rail strikes currently planned for Wednesday 27, Saturday 31 of July.
-
CAMLIS is the Royal London Hospital for Integrated Medicine (RLHIM) Complementary and Alternative Medicine Information and Library Service and is situated on the ground floor of the hospital.
-
UCLH will play a vital role in a new respiratory virus study.
-
UCLH is celebrating the delivery of its 1,000th respiratory syncytial virus (RSV) vaccine to pregnant women, following the rollout of the new national programme in September.
-
UCLH and UCL are at the forefront of Women’s Health care and research – across areas including reproductive health, maternity, breast care, care for newborns, gynaecological care, and cancer.
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
This page has been written by the team in the mitochondrial clinic for patients who are seen at the National Hospital for Neurology and Neurosurgery, who have a diagnosis of mitochondrial disease.
File results
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0513 - Robotic platforms for surgery costs/ contract
-
FOI/2024/0514 - Viscosupplementation injections/ spend
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer